Oegstgeest, Netherlands

Tom H M Ottenhoff

This inventor holds 3 USPTO granted patents. Top assignee: Academisch Ziekenhuis Leiden. Active years: 2015-2019.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Tom H M Ottenhoff. Retrieved from https://idiyas.com/inventor/tom-h-m-ottenhoff

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


Average Co-Inventor Count = 8.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2015-2019

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Innovations in Immunology: The Contributions of Tom H M Ottenhoff

Introduction

Tom H M Ottenhoff is a notable inventor based in Oegstgeest, Netherlands. He has made significant contributions to the field of immunology, particularly in the development of long peptides that enhance antigen-specific immune responses. With a total of 3 patents, Ottenhoff's work is pivotal in advancing vaccination strategies against various infections and cancers.

Latest Patents

Ottenhoff's latest patents focus on long peptides of 22-45 amino acid residues that induce and enhance antigen-specific immune responses. These peptides are derived from human papilloma virus and are designed to immunize subjects against (Myco) bacterially and/or virally infected cells or tumor cells. His research demonstrates that peptide sequences of 22-35 amino acid residues can induce both peptide-specific CD8+ cytolytic cells and CD4+ T-helper cells. Furthermore, vaccination with these longer peptides results in a more vigorous CD8+ cytolytic T-cell response compared to shorter peptides. Ottenhoff's work also addresses the challenges posed by certain minimal CTL epitopes that can tolerize cytolytic cells, providing innovative solutions for effective vaccination and treatment against HPV and related conditions.

Career Highlights

Tom H M Ottenhoff is affiliated with Academisch Ziekenhuis Leiden, where he continues to explore the potential of peptide-based immunotherapies. His research has garnered attention for its clinical relevance and potential impact on treating progressive lesions and cervical cancer.

Collaborations

Ottenhoff collaborates with esteemed colleagues such as Sjoerd Hendrikus Van Der Burg and Annemieke Geluk, contributing to a robust research environment focused on immunological advancements.

Conclusion

Tom H M Ottenhoff's innovative work in immunology, particularly through his patented peptides, represents a significant advancement in the field. His contributions are essential for developing effective vaccines and treatments for various diseases.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…